Cinchophen

Gout is a metabolic disease with high incidence worldwide, and traditional anti-inflammatory and analgesic drugs often have the clinical limitation of frequent gastrointestinal adverse reactions. As a classic non-steroidal anti-inflammatory and analgesic drug, cinchophen reduces the synthesis of prostaglandins by inhibiting the activity of cyclooxygenase, and has the dual effects of anti-inflammation, analgesia and promoting uric acid excretion. It is mainly used clinically to relieve the symptoms of acute gouty arthritis, and can also assist in improving the joint swelling and pain caused by rheumatic arthritis and rheumatoid arthritis. The applicable population covers adult patients in the acute attack stage of gout and those who cannot tolerate the adverse reactions of other NSAIDs.

At present, the global market size of cinchophen is about USD 120 million, and the compound annual growth rate in the past 3 years has maintained at around 4.7%. The growth driver mainly comes from the expansion of anti-inflammatory and analgesic demand brought by the rising prevalence of gout in emerging markets. In terms of competitive landscape, generic drugs account for 89% of the overall market share, and the main production areas are concentrated in China and India. Among them, Chinese-made cinchophen API has occupied 62% of the global generic drug raw material supply market due to its stable purity and low production cost. There is no winning record related to centralized procurement at present, and the market supply is mainly based on market-oriented negotiation.

The original research enterprise of cinchophen is Bayer AG of Germany, and the original research trade name is Atophan. The core compound patent expired in 1940, and there is no valid core patent at present. The main dosage form of the original research product that has been launched is tablet, with the specification of 0.25g per tablet. The original research product is not included in the Chinese *Catalogue of Reference Preparations for Chemical Drugs*, nor has it been approved for marketing in China. At present, there is no approved cinchophen registration number in A status on the domestic API registration platform. Only the registration number submitted by 1 enterprise is in I status, which has not passed the associated evaluation and approval for the time being, and there is no cinchophen preparation product approved for marketing in China either. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for cinchophen API. Most products support spot supply. For in-stock products, orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can meet the reference standard use needs of pharmaceutical enterprises in the whole process of raw material R&D, quality research, declaration and registration, etc.